Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumorigenesis relies on oncogenes activating cell proliferation and survival signaling pathways, often regulated by protein phosphorylation.
• Protein kinases are established drug targets in cancer therapy, with numerous inhibitors in clinical use.
• The role of protein phosphatases, like Ser/Thr phosphatase 2A (PP2A), in cancer is increasingly recognized.

Purpose of the Study:

• To explore the development of small molecule modulators targeting protein Ser/Thr phosphatase 2A (PP2A).
• To investigate the potential of PP2A modulation to inhibit cancer cell proliferation and survival pathways.
• To assess the therapeutic potential of PP2A-activating drugs for cancer and other human diseases.

Main Methods:

• Development of novel small molecules designed to modulate PP2A activity.
• Investigation of PP2A modulators' effects on the assembly of specific heterotrimeric PP2A forms.
• Assessment of PP2A modulator impact on cell proliferation and survival signaling pathways.

Main Results:

• Novel small molecules were developed that effectively modulate PP2A.
• These modulators promote the assembly of specific heterotrimeric PP2A complexes.
• The enhanced PP2A activity leads to the limitation of cancer cell proliferation.

Conclusions:

• Small molecule activation of PP2A represents a promising therapeutic strategy for cancer.
• Targeting PP2A assembly offers a novel approach to inhibit oncogenic signaling.
• This strategy holds potential for near-term clinical translation in oncology and other diseases.